Alpha-1 Antitrypsin Deficiency Disease Treatment Market Size

The global alpha-1 antitrypsin deficiency disease treatment market size accounted for USD 2.6 billion in 2023 and is expected to grow at 10.1% of CAGR from 2024 to 2032. The growth of the market is driven by several factors, including the rising prevalence of AATD-related respiratory and liver diseases, increased awareness and screening programs, advancements in diagnostic technologies, and the development of effective treatment options.

Additionally, the growing number of cases of chronic obstructive pulmonary disease (COPD), liver cirrhosis, and other conditions related to AATD is significantly boosting market growth. For instance, according to the American Lung Association, there are between 80,000 to 100,000 people in the U.S. living with alpha-1 antitrypsin (AAT) deficiency, putting them at greater risk for developing COPD. This highlights the critical need for effective interventions and therapies.

Furthermore, advancements in diagnostic technologies have been crucial for the early detection and treatment of AATD-related disorders. New diagnostic tools now allow healthcare providers to identify AATD earlier, enabling timely and personalized treatment plans, thereby propelling market growth.

AAT is a protein made in the liver that helps protect the lungs. Alpha-1 antitrypsin deficiency increases the risk of lung and other diseases. If the body does not produce enough AAT, the lungs become more vulnerable to damage from smoking, pollution, and dust. Treatment for AATD includes diagnostics, therapeutics, and preventive measures targeting AATD-related conditions. Treatment options include augmentation therapy with purified alpha-1 antitrypsin protein, gene therapy, inhaled therapies, liver transplantation for severe cases, and lifestyle changes.